1-20 of 34
Anita K Gandhi, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma

Nicholas J. Boddicker, PhD, Pinkal Desai, MDMPH, Mithun Vinod Shah, MD PhD, Vivekananda Sarangi, Matthew J. Maurer, MS, Elliot J. Cahn, Peter Martin, FRCPC, MD MS, Brian K. Link, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Grzegorz S. Nowakowski, MD, Thomas M. Habermann, MD, Susan L. Slager, PhD, C. Chris Huang, PhD, Fadi Towfic, PhD, Yan Asmann, PhD, Anita K Gandhi, PhD, Anne J. Novak, PhD, James R. Cerhan, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-141726
Published: 2020
Journal Articles

Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia

Andrew Lipsky, MD, Danny Luan, MPH, Shirley Chen, BSc, Ronan Chaligne, PhD, Neville Dusaj, MS, Erica B Bhavsar, BS, Chelston Ang, MS, Anna S Nam, MD, Federico Gaiti, PhD, Paulina Chamely, MSc, Nathaniel D. Omans, MS, Preeti Trisal, MS, Anita K Gandhi, PhD, Kyu-Tae Kim, PhD, Rafael Schulman, BS, Joshua S. Schiffman, PhD, Franco Izzo, PhD, Gregory Mullokandov, MD PhD, Chingiz Underbayev, MD PhD, Adrian Wiestner, MD PhD, John N. Allan, MD, Richard R. Furman, MD, Dan A. Landau, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-138374
Published: 2020
Journal Articles

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Nikolaos Ioannou, PhD MSc, BSc, Patrick R. Hagner, PhD, Fadi Towfic, PhD, Anita K. Gandhi, PhD, Kostas Stamatopoulos, MD PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Anna Vardi, MD PhD, Alan G. Ramsay, BSc,MSc,PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 237.
https://doi.org/10.1182/blood-2018-99-111605
Published: 2018
Journal Articles

Mechanism of Synergistic Effects on T Cell Activation By Avadomide (CC-122) and Nivolumab

Yumi Nakayama, PhD, Matthew E. Stokes, PhD, Michelle Waldman, MS, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4133.
https://doi.org/10.1182/blood-2018-99-114469
Published: 2018
Journal Articles

Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients

Patrick R. Hagner, PhD, Fadi Towfic, PhD, Frank Schmitz, MD PhD, Xuehai Wang, PhD, Andrew P. Weng, MD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4211.
https://doi.org/10.1182/blood-2018-99-114481
Published: 2018
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD, Fontanet Bijou, MD, Vincent Ribrag, MD, Julio C. Chavez, MD, Thomas E. Witzig, MD, David J. Andorsky, MD, Leonard M. Klein, MD, Daniel Greenwald, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Shailaja Uttamsingh, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Tianlei Chen, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2018-99-114409
Published: 2018
Journal Articles

A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study

Cecilia Carpio, MD, Reda Bouabdallah, MD, Loic Ysebaert, MD PhD, Juan-Manuel Sancho, MD PhD, Gilles Salles, MD PhD, Raul Cordoba, MD PhD, Antonio Pinto, MD, Mecide Gharibo, MD, Drew W. Rasco, MD, Carlos Panizo, MD PhD, Jose A. Lopez-Martin, MD PhD, Armando Santoro, MD, Antonio Salar, MD PhD, Silvia Damian, MD, Alejandro Martín, MD PhD, Gregor Verhoef, MD PhD, Xin Wei, Patrick R. Hagner, PhD, Kristen Hege, MD, Alberto Risueño, PhD, Anita K. Gandhi, PhD, Tonia J. Buchholz, PhD, Michael Pourdehnad, MD, Vincent Ribrag, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4118.
https://doi.org/10.1182/blood.V130.Suppl_1.4118.4118
Published: 2017
Journal Articles

Discovery of an Immune-Driven Gene Expression Signature That Predicts for Clinical Benefit to CC-122 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Alberto Risueño, PhD, Patrick R. Hagner, PhD, Celia Fontanillo, PhD, Amira Djebbari, DSc, Joel S. Parker, PhD, Clifton P. Drew, PhD, Fadi Towfic, PhD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD, Matthew Trotter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2830.
https://doi.org/10.1182/blood.V130.Suppl_1.2830.2830
Published: 2017
Journal Articles

Combination of Lenalidomide and Rituximab (R 2 ) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy

Hsiling Chiu, Patrick R. Hagner, PhD, Preeti Trisal, Michelle Waldman, Chloe Cavanaugh, Anita K. Gandhi, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1531.
https://doi.org/10.1182/blood.V130.Suppl_1.1531.1531
Published: 2017
Journal Articles

CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Vincent Ribrag, Julio C. Chavez, MD, Umberto Vitolo, MD, Jason B. Kaplan, MD, Jason C. Chandler, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Loretta Nastoupil, MD, Philippe A. Cassier, MD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Ranjana H. Advani, MD, Iris Isufi, MD, Thomas E Witzig, MD, Michael Petrarca, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Xiaoling Wu, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1551.
https://doi.org/10.1182/blood.V130.Suppl_1.1551.1551
Published: 2017
Journal Articles

CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2016) 128 (22): 1591.
https://doi.org/10.1182/blood.V128.22.1591.1591
Published: 2016
Journal Articles

CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2016) 128 (22): 1592.
https://doi.org/10.1182/blood.V128.22.1592.1592
Published: 2016
Journal Articles

CC-122 Exhibits Greater Preclinical Activity in Mantle Cell Lymphoma Than Lenalidomide through a Combination of Direct Cell-Autonomous and Increased Antibody Dependent Cell-Mediated Cytotoxicity

Patrick R. Hagner, Hsiling Chiu, Michelle F. Waldman, Anke Klippel, PhD, Michael Pourdehnad, Anita K. Gandhi, PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2016) 128 (22): 4188.
https://doi.org/10.1182/blood.V128.22.4188.4188
Published: 2016
Journal Articles

Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, MD, Betsy R. Laplant, MS, Levi Pederson, Matthew J Maurer, MS, William R. Macon, MD, Rebecca L King, MD, James Storhoff, Shannon Dennis, Anita K. Gandhi, PhD, Anjan Thakurta, PhD, Patrick R. Hagner, Lisa Rimsza, MD, Thomas M. Habermann, James R Cerhan, MD PhD, Thomas E. Witzig, MD
Journal: Blood
Blood (2016) 128 (22): 3035.
https://doi.org/10.1182/blood.V128.22.3035.3035
Published: 2016
Journal Articles

A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001

Vincent Ribrag, MD, Julio C. Chavez, MD, Jason B Kaplan, MD, Umberto Vitolo, MD, Jason C. Chandler, MD, Armando Santoro, MD, Paolo Corradini, MD, Philippe Cassier, MD, Ian W. Flinn, MD PhD, Ranjana Advani, MD, Randeep Sangha, Iris Isufi, MD, Vaishalee P. Kenkre, MD, Patrick R. Hagner, Torsten Trowe, PhD, Anita K. Gandhi, PhD, Xiaoling Wu, PhD, Kristen Hege, MD, Michael Pourdehnad, John Kuruvilla, MD
Journal: Blood
Blood (2016) 128 (22): 1849.
https://doi.org/10.1182/blood.V128.22.1849.1849
Published: 2016
Journal Articles

Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity

Patrick Hagner, PhD, Hsiling Chiu, Maria Ortiz-Estevez, Tsvetan Biyukov, Carrie Brachman, Marek Trneny, Luca Arcaini, Franck Morschhauser, MD, Antoine Thyss, Stephan Stilgenbauer, Noel Milpied, Reinhard Marks, Pellegrino Musto, Giovanni Martinelli, MD PhD, Carla Heise, Thomas Daniel, Rajesh Chopra, James Carmichael, Matthew Trotter, Anita K. Gandhi, PhD, Anjan Thakurta
Journal: Blood
Blood (2015) 126 (23): 821.
https://doi.org/10.1182/blood.V126.23.821.821
Published: 2015
Journal Articles

CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity

Hsiling Chiu, Patrick Hagner, PhD, Michael Pourdehnad, MD, Thomas Daniel, Rajesh Chopra, Anke Klippel, Christian Klein, PhD, Anjan Thakurta, Anita K. Gandhi, PhD
Journal: Blood
Blood (2015) 126 (23): 4007.
https://doi.org/10.1182/blood.V126.23.4007.4007
Published: 2015
Journal Articles

Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile

Michael D. Amatangelo, PhD, Paola Neri, MD PhD, Maria Ortiz, PhD, Chad C. Bjorklund, Anita K. Gandhi, PhD, Anke Klippel, Nizar J Bahlis, MD, Tom Daniel, Rajesh Chopra, MBBS, PhD, Matthew Trotter, Anjan Thakurta
Journal: Blood
Blood (2015) 126 (23): 1789.
https://doi.org/10.1182/blood.V126.23.1789.1789
Published: 2015
Journal Articles

CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Cecilia Carpio, MD, Loïc Ysebaert, MDPhD, Raúl Cordoba, MD, Armando Santoro, MD, José Antonio López-Martín, MD, Juan Manuel Sancho, MD PhD, Carlos Panizo, PhD, Mecide Meric Gharibo, MD, Drew W Rasco, MD, Anne-Marie Stoppa, MD, Sylvia Damian, MD, Xin Wei, Patrick Hagner, PhD, Kristen Hege, Soraya Carrancio, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Vincent Ribrag, MD
Journal: Blood
Blood (2015) 126 (23): 1494.
https://doi.org/10.1182/blood.V126.23.1494.1494
Published: 2015
Journal Articles

IMiD® Immunomodulatory Agents Promote Apoptosis in Multiple Myeloma Cells through Induction of TRAIL Expression

Michael D. Amatangelo, PhD, Chad C. Bjorklund, Anita K. Gandhi, PhD, Anke Klippel, Tom Daniel, Rajesh Chopra, MBBS, PhD, Matthew Trotter, Anjan Thakurta
Journal: Blood
Blood (2015) 126 (23): 5355.
https://doi.org/10.1182/blood.V126.23.5355.5355
Published: 2015